Subscribe to Angie's Blog

image

COVID-19 Vaccines and Treatments

  • Adverse Events Reported After COVID-19 Vaccination (Released 3/9/21)
    CDC and FDA scientists have evaluated reports from people who experienced a type of severe allergic reaction, anaphylaxis, after getting a COVID-19 vaccine. Anaphylaxis after COVID-19 vaccination is rare and occurred in approximately 2 to 5 people per million vaccinated in the United States based on events reported to VAERS. This kind of allergic reaction almost always occurs within 30 minutes after vaccination. Fortunately, vaccination providers have medicines available to effectively and immediately treat patients who experience anaphylaxis following vaccination.
  • AHCA/NCAL COVID-19 Facility Vaccine Clinic Checklist v1 (Created 12/14/20)
    AHCA/NCAL has created the checklist for use when administering vaccines.
  • AMDA Letter To Families COVID Vaccine (Released 12/23/20)
    The Society for Post-Acute and Long-Term Care Medicine have provided a letter that facilities can use to inform families about the safety of the COVID-19 vaccines.
  • AMDA - Q&A about the COVID-19 Vaccine for PALTC Patients Family Member and Staff Dec 1, 2020
    The Society for Post-Acute and Long-Term Care Medicine has released a Q&A about the COVID-19 vaccine.
  • ASPR TRACIE Planning Considerations for Monoclonal Antibody Administration (posted 8/11/21)
    Tip sheet from TRACIE updated February 10, 2021.
  • Assessment and Testing - Evaluating and Caring for Patients with Post-COVID Conditions: Interim Guidance (Posted 7/15/21)
    Before ordering laboratory testing for post-COVID conditions, the goals of testing should be clear to the healthcare professional and to the patient. Laboratory testing should be guided by the patient history, physical examination, and clinical findings.
  • Bamlanivimab EUA for COVID-19 v1 (Released 1/5/21)
    The investigational neutralizing IgG1 monoclonal antibody bamlanivimab (LY-CoV555; Lilly) has been granted an FDA Emergency Use Authorization (EUA) for treatment of recently diagnosed mild to moderate COVID-19 in patients who are ≥12 years old, weigh at least 40 kg, and are at high risk for progressing to severe disease and/or hospitalization. Eligibility for patients considered high risk.
  • Booster Checklist Provided by JAMA (Posted 9/22/21)
    Checklist for preparation for booster immunization in PALTC
  • CDC Advisory Committee on Immunization Practices v1 (Released 12/9/20)
    The Advisory Committee on Immunization Practices (ACIP) is a group of medical and public health experts that develops recommendations on how to use vaccines to control diseases in the United States. This document answers questions about the ACIP such as how it makes decisions about vaccine recommendations, what the ACIP considers in the vaccine recommendation process, and where you can find their vaccine recommendations.
  • CDC Considerations for Additional mRNA Vaccine (Posted 8/25/21)
    On August 13, 2021, ACIP met and reviewed the data for use of an additional dose of mRNA COVID-19 vaccine for immunocompromised people within the Evidence to Recommendation Framework. ACIP made an interim recommendation for use of an additional dose of Pfizer-BioNTech COVID-19 vaccine (for persons aged ≥ 12 years) or Moderna COVID-19 vaccine (for persons aged ≥ 18 years) after an initial 2-dose primary mRNA COVID-19 vaccine series for moderately to severely immunocompromised people.
  • CDC Considerations for Interpretation of Antigen Tests in LTC (Posted 1/26/21)
    The CDC has put forth an algorithm for interpreting antigen tests in long-term care facilities.
  • CDC Facts about COVID-19 vaccines (Posted 1/8/21)
    A flyer from the CDC with facts about the COVID-19 vaccine
  • CDC FAQs COVID 19 Vaccines V2 (Posted 5/6/22)
    CDC has answers to commonly asked questions about COVID-19 vaccination. CDC also has information for busting common vaccine myths available in facts about COVID-19 vaccines.
  • CDC Guidance - Vaccine Coadministration (Posted 7/15/21)
    COVID-19 vaccines and other vaccines may now be administered without regard to timing. This includes simultaneous administration of COVID-19 vaccine and other vaccines on the same day, as well as coadministration within 14 days.
  • CDC – Infection Post-Vaccination v1 (Posted 5/6/21)
    CDC has some information for those who contract COVID-19 after vaccination
  • CDC Interim Clinical Considerations for Use of mRNACOVID-19 Vaccines Currently Authorized in the United States (Posted 2/23/21)
    CDC summary of recent changes, last updated February 10, 2021
  • CDC Management of Anaphylaxis at COVID-19 Vaccination Site (Posted 12/28/20)
    Anaphylaxis is an acute and potentially life-threatening serious allergic reaction. Severe allergic reaction (e.g., anaphylaxis) to a previous dose of any COVID-19 vaccine or any component of the COVID-19 vaccine listed in the prescribing information is a contraindication to vaccination. A history of a severe allergic reaction to any other vaccine or injectable therapy is a precaution to vaccination.
  • CDC Pfizer COVID-19 Vaccine Standing Orders for Administering Vaccine (12/17/20)
    To reduce morbidity and mortality from coronavirus disease 2019 (COVID-19) by vaccinating persons who meet the criteria established by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP)
  • CDC Post COVID Care-Considerations v1 (Posted 7/7/21)
    It is important for healthcare professionals to listen to and validate patients’ experiences, recognizing that diagnostic testing results may be within normal ranges even for patients whose symptoms and conditions negatively impact their quality of life, functioning (i.e., with activities of daily living), and ability to return to school or work.
  • CDC Post COVID Care Key Points v1 (Posted 7/7/21)
    Evaluating and Caring for Patients with Post-COVID Conditions: Interim Guidance – Key Points
  • CDC Pre-Vaccination Screening Form (Posted 12/28/20)
    The following questions will help us determine if there is any reason you should not get the COVID-19 vaccine on that particular day. If you answer “yes” to any question, it does not necessarily mean you should not be vaccinated. It just means additional questions may be asked.
  • CDC Product Information Guide for COVID-19 Vaccines v1 (Released 12/4/20)
    This guide provides specifications for COVID-19 vaccine and associated products. This is NOT a catalog from which you can order products. It provides key product information including product package dimensions and weight, minimum order quantities, product presentation, distribution method, storage information, and additional information. This guide will be updated as more products become available.
  • CDC Proper Sharps Disposal (Posted 4/29/21)
    Safe and Proper Sharps Disposal During the COVID-19 Mass Vaccination Campaign
  • CDC Recommendations Fully Vaccinated v1 (Posted 5/11/21)
    This set of public health recommendations for fully vaccinated people will be updated and expanded based on the level of community spread of SARS-CoV-2, the proportion of the population that is fully vaccinated, and the rapidly evolving science on COVID-19 vaccines.
  • CDC Recommendations COVID Vaccine v1 (Released 12/22/20)
    On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 (BNT162b2) vaccine. The vaccine consists of 2 doses (30 μg, 0.3 mL each) administered intramuscularly, 3 weeks apart. On December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥ 16 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP employed the Evidence to Recommendation (EtR) Framework, using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach. The recommendation for the Pfizer-BioNTech COVID-19 vaccine should be implemented in conjunction with ACIP’s interim recommendations for allocating initial supplies of COVID-19 vaccines. The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine under EUA is interim and will be updated as additional information becomes available.